Venture Life Investors - VLG

Venture Life Investors - VLG

Buy
Sell
Best deals to access real time data!
Silver
Monthly Subscription
for only
£17.37
Level 2 Basic
Monthly Subscription
for only
£62.08
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Venture Life Group Plc VLG London Ordinary Share GB00BFPM8908 ORD 0.3P
  Price Change Price Change % Stock Price Last Trade
0.00 0.0% 87.00 07:42:45
Open Price Low Price High Price Close Price Previous Close
87.00
more quote information »
Industry Sector
HEALTH CARE EQUIPMENT & SERVICES

Top Investor Posts

DateSubject
29/3/2021
12:31
simon gordon: Just a reminder that the Investor Meet video call starts at 1pm with the CEO, CFO and CCO: Https://www.investormeetcompany.com/
25/3/2021
12:06
lammylover: Looks like we may have to wait for news of acquisitions, but that's fine. I'd rather the Board spent longer doing their due diligence and getting a complementary business at the right price, rather than rushing to use the fund raise monies. This is a strong company in growth sector which should accelerate its performance as CV19 lockdown lifts and customers return to the high street. I'd expect Simon Thompson in IC to continue to rate a Buy, based on LY results. Share price will probably bounce over 90p as soon as he lists it on line / via Investors Chronicle magazine. Happy to hold for further gains. Rich
03/3/2021
10:15
red ninja: The company is also doing a InvestorMeetCompany webinar. I am not sure why they would want to do that if they don't think there is a reasonable story to sell. https://www.investegate.co.uk/venture-life-group--vlg-/rns/investor-presentation/202102250700042439Q/
03/3/2021
10:06
frankwhite: My original suspicions that the imminent aquisition was being delayed/having issues still holds true. Looking at the calibre of investors in the open offer is no justification to follow them blindly. I also took up the open offer at 80p and which I oversubscribed for. Once I saw no progress taking place I had my suspicions and sold all of them. Until there is news I won't be investing here but GLA just be careful not to follow others like sheep. Remember Lakehouse one of Mark Slater's investments, it went nowhere and think has gone private now where investors lost out significant sums, another that I'm sure you all remember is Quindell where intis all got caught out with major loses.
01/2/2021
13:02
simon gordon: Mark Slater talking about his methodology the other day: Trustnet - 28/1/21 ...Slater, who seeks growth at an equitable price, is the son of renowned UK investor Jim Slater, who died in 2015 and coined the “Zulu Principle”, a strategy that combines growth, value, quality, and momentum factors. Using price-to-earnings growth as a measure, the strategy compares a company’s forecast price-to-earnings ratio with its forecast earnings-per-share growth rate, which is currently deployed as a screening mechanism in the fund. “We’re not interested in price-to-book,” said Slater, highlighting a three-pronged approach to screening stocks. “We want companies that are growing at a double-digit rate in earnings terms,” he said. “Secondly, [we consider whether you] can you buy that growth cheaply, and the third is profit conversion into cash. Hence price-to-cash flow is important as we want the cash flow per share to be in excess of earnings per share.” Slater explained those three screens eliminate 95 per cent of the UK market and would do something similar if applied to most markets. “Most companies are not growing,” said the manager. “Or if they are, they’re very expensive or they’re not generating cash.” A shortlist is collated which then requires further analysis into how reliable that growth rate is. “Then the work goes from being entirely quantitative to entirely qualitative,” he said. “Is there a tangible tailwind which his driving that growth? It’s why our businesses are quite niche; they’re doing one or two things but are doing them exceptionally well.” Https://www.trustnet.com/news/5253626/mark-slater-the-bell-has-been-rung-and-people-are-coming-back-to-the-uk
01/2/2021
09:55
simon gordon: Cenkos have issued a note. Cash adjusted 14x 2021. 2021 year end cash £36.3m. They delivered on expectations. I don't see the big issue with raising cash, they are in the business to grow and business changes and opportunities arise. Being agile and flexible is a positive not a negative. Some China sales have moved into H1 2021 and they still met expectations. I'd judge them more on the next trading update, it's far too early in the year to throw mud at them. Slater going from 5% to 15% in the placing shows one of the best small cap investors in the London market having conviction in management, the business and future growth drivers.
25/11/2020
22:17
whatja: FB looks like your percentages or timeline is wrong.....SP has been above 80 since August. There has been a series of positive updates this year. They have got a big fund raise away ata decent price....yes it was unexpected, probably triggered by the change to preemption rights and concern about CGT rises for the BOD, but only v recent investors have suffered any real losses. The new institutional investors will not want a price collapse. The deals seem reasonable and feasible. They will be well funded. What is not to like? My worry list would be can they get paid by their big Chinese distributor? Will they overpay for the acquisitions? Can they innovate to improve what they buy? We will see how the working capital is with the FY results They have set out the price they expect to pay so we should know if they overpay They have some innovation in their products.
23/11/2020
16:49
speedsgh: Yes, brief Simon Thompson update today following the fundraising announcement last week. Reiterates BUY recommendation and also recommends taking up Open Offer entitlements... HTTPS://www.investorschronicle.co.uk/comment/2020/11/23/bagging-a-value-stock-hat-trick/ "... The fact that the £34m placing proceeds have been conditionally placed at 90p with institutional and other investors highlights significant backing for the scaling up of Venture’s acquisition strategy. It’s also likely to lead to material upgrades in due course given the accompanying boost to operating profits and margins."
20/11/2020
15:46
rivaldo: IMO the share price will rise again as investors realise the potential and implications of the likely acquisitions. The Investor's Champion comment seems ridiculously OTT to me. No credit is given for the turnaround in recent times - which was taking root well before COVID - or for the directors' selling being mainly that of the founders, who set up the business a long time ago in 2010. Surely they're allowed to enjoy (admittedly too sizeable imo) fruits of their recent success, whilst retaining significant stakes? As for the "foolish" institutions, this is a dramatic change of tune from Investor's Champion - who only two days ago said about VLG: A reasonably valued healthcare company, there must be a catch"!
20/11/2020
09:07
rivaldo: Good to see VLG newly tipped on Investors' Champion - subscriber-only though: Https://www.investorschampion.com/channel/blog/a-reasonably-valued-healthcare-company-surely-there-must-be-a-catch "A reasonably valued healthcare company, there must be a catch! (Updated) 18/11/2020 · Venture Life Group PLC (VLG) Many healthcare companies, especially with anything relating to aiding Covid-19, have benefited from a strong share price over the pandemic and it is rare to find something of seemingly reasonable value. The shares received another boost on news that its mouthwash might be effective against COVID-19. Check out our updated research here. Founded in 2010, Venture Life Group (LON:VLG) is an international consumer healthcare company focused on developing and manufacturing non-drug self-care products for the ageing population, which consumers can buy without prescription. The Group's manufacturing is based in Italy, where a 5,500m² factory is being expanded to produce up to 55 million units per annum by the end of the year, producing both Venture Life's own brands as well as products for others as a contract manufacturer. With over 35 years of experience, the site boasts exciting development capabilities thanks to superior laboratory facilities and knowledge of the market. The Group has 10 branded products, covering…"
ADVFN Advertorial
Your Recent History
LSE
VLG
Venture Li..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210413 07:04:42